CMS Unveils Negotiated Prices for Ozempic, Wegovy, and Other Drugs in Second Round of IRA Talks
CMS negotiated a 71% discount on Ozempic, Rybelsus, and Wegovy, resulting in a $274 monthly price for Ozempic/Rybelsus and $385 for Wegovy for a 30-day supply.
The new prices for 15 high-spending drugs, including Ozempic, Wegovy, and others, will take effect January 1, 2027.
These negotiated prices could have saved Medicare $12 billion and beneficiaries $685 million in out-of-pocket costs if in effect during 2024.
The second round of negotiations included drugs for diabetes, cancer, asthma, and other chronic illnesses.
Semaglutide (Ozempic, Wegovy, Rybelsus) was treated as a single product for negotiation, regardless of indication or formulation.
Other drugs in the second round include Janumet, Austedo, Ibrance, Ofev, Linzess, Calquence, Breo Ellipta, Tradjenta, Xifaxan, Vraylar, and Otezla.